Tolerability of the triptans: Clinical implications

Drug Safety

Volumn 26, Issue 2, 2003, Pages 93-107

  Nappi, Giuseppe ^a,b   Sandrini, Giorgio ^a   Sances, Grazia ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; ELETRIPTAN; ERGOT DERIVATIVE; MONOAMINE OXIDASE INHIBITOR; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; RIZATRIPTAN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN DERIVATIVE; ZOLMITRIPTAN;

ANGINA PECTORIS; ARTERIOSCLEROSIS; BURNING SENSATION; CARDIOTOXICITY; CLINICAL TRIAL; DROWSINESS; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG LABELING; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INJECTION PAIN; LIVER METABOLISM; MALAISE; MIGRAINE; MUSCLE STIFFNESS; MUSCLE WEAKNESS; NAUSEA; NECK MUSCLE; NECK PAIN; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PERCEPTION DISORDER; PREMATURE LABOR; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; RISK ASSESSMENT; SEDATION; SEROTONIN SYNDROME; SKIN TINGLING; SOMNOLENCE; TASTE AVERSION; TASTE DISORDER; TERATOGENICITY; THORAX DISEASE; THORAX PAIN; THROAT DISEASE; VERTIGO; VOMITING;

BRAIN; CARDIOVASCULAR SYSTEM; DRUG INTERACTIONS; FEMALE; FETUS; HUMANS; MIGRAINE DISORDERS; PREGNANCY; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0037275120     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326020-00003     Document Type: Review

References (146)

1. Saxena PR, De Vries P, Villalòn CM. 5-HT1-like receptors: a time to bid goodbye. Trends Pharmacol Sci 1998; 19: 311-6
2. De Vries P, Villalòn CM, Saxena PR. Pharmacology of triptans. Emerg Drugs 1999; 4: 107-25
3. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine. Drugs 2000; Dec 60 (6): 1259-87
4. Saxena PR, Tfelt-Hansen P. Triptans, 5-HT1B/1D receptor agonists in the acute treatment of migraine. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. Philadelphia (PA): Lippincot Williams & Wilkins, 2000
5. Tfelt-Hansen P. Sumatriptan for the treatment of migraine attacks: a review of controlled clinical trials. Cephalalgia 1993; 13: 238-44
6. Plosker GL, McTavish D. Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994; 47: 622-51
7. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 1991; 31: 295-9
8. Tansey MJB, Pilgrim AJ, Martin PM. Long-term experience with sumatriptan in the treatment of migraine. Eur Neurol 1993; 33: 310-5
9. Nappi G, Sicuteri F, Byrne M, et al. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 1994; 241: 138-44
10. Perry CN, Markham A. Sumatriptan: an updated review of its use in migraine. Drugs 1998; 55: 889-922
11. Schoenen J. Acute migraine therapy: the newer drugs. Curr Opin Neurol 1997; 10: 237-43
12. Jhee SS, Shiovitz T, Crawford AW, et al. Pharmacokinetics and pharmacodynamics of the triptans antimigraine agents. Clin Pharmacokinet 2001; 40 (3): 189-205
13. Brion N, Bons J, Plas J, et al. Initial clinical experience with the use of subcutaneous GR43175 in treating acute migraine. Cephalalgia 1989; 9 Suppl. 9: 79-82
14. Cabarrocas X, Esbri R, Peris F, et al. Long-term efficacy and safety of oral almotriptam: interim analysis of a 1-year open study. Headache 2001; 41: 57-62
15. Caro JJ, Getsios D, Raggio G, et al. Treatment of migraine in Canada with naratritpan: a cost-effectiveness analysis. Headache 2001; 41: 456-64
16. Dahlöf C, Hogenhuis L, Olesen J, et al. Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. Eur J Neurol 1998; 5 (5): 469-77
17. Bomhof MAM, Heywood J, Pradalier A, et al. Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Cephalalgia 1998; 18: 33-7
18. Brown EG, Endersby CA, Smith RN, et al. The safety and tolerability of sumatriptan: an overview. Eur Neurol 1991; 31: 339-44
19. Deleu D, Hanssens Y. Current and emerging second-generation triptans in acute migraine therapy: a comparative review. J Clin Pharmacol 2000; 40: 687-700
20. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668-75
21. Gawel MJ, Worthington I, Maggisano A. A systematic review of the use of triptans in acute migraine. Can J Neurol Sci 2001; 28: 30-41
22. Goadsby PJ. The scientific basis of medication choice in symptomatic migraine treatment. Can J Neurol Sci 1999; 26 Suppl. 3: S20-6
23. Diener HC, Kaube H, Limmroth V. Antimigraine drugs. J Neurol 1999; 246: 515-9
24. Lipton RB, Pascual J, Goadsby PJ, et al. Effect of rizatriptan and other triptans on the nausea symptoms of migraine: a post hoc analysis. Headache 2001; 41: 754-63
25. Millson DS. Rational migraine management: optimising treatment with the triptans. Funct Neurol 2000; (15) Suppl. 3: 182-91
26. Rapoport AM, Tepper SJ. Triptans are all different. Arch Neurol 2001 Sep; 58: 1479-80
27. Tepper SJ, Rapoport AM. The triptans: a summary. CNS Drugs 1999; 12: 403-17
28. Diener HC, Limmroth V. Acute management of migraine: triptans and beyond. Curr Opin Neurol 1999; 12: 261-7
29. Diener HC, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine. Drugs 1998 Nov; 56 (5): 811-24
30. De Vries P, Villatòn CM, Saxena PR. Pharmacological aspects of experimental headache in relation to acute migraine antimigraine therapy. Eur J Pharmacol 1999; 375: 61-74
31. 1B/1Dagonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalagia 2002; 22: 633-58
32. Fowler PA, Thomas M, Lacey LF, et al. Early studies with the novel 5-HT1-like agonists GR43175 in healthy volunteers. Cephatalgia 1989; 9 Suppl. 9: 57-62
33. Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine. Neurology 2000; 54: 156-63
34. Heywood J, Bomhof MAM, Pradalier A, et al. Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Cephalalgia 2000; 20: 470-4
35. Kunka RL, Hussey EK, Shaw S, et al. Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers. Cephalalgia 1997; 17: 532-40
36. Luciani R, Carter D, Mannix L, et al. Prevention of migraine during prodrome with naratriptan. Cephalatgia 2000; 20: 122-6
37. Moore KHP, Hussey EK, Shaw S, et al. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalalgia 1997; 17: 541-50
38. Nappi G, Neil JF. The clinical efficacy of zolmitriptan. Rev Contemp Pharmacother 2000; 11 (2): 99-116
39. Pascual J, Falk R, Docekal R, et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur Neurol 2001; 45: 206-13
40. Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia 2000; 20: 588-96
41. Pascual J, Muñoz R, Leira R. An open preference study with sumatritptan 50mg and zolmitriptan 2.5mg in 100 migraine patients. Cephalalgia 2001; 21: 680-4
42. Putnam GP, O'Quinn S, Bolden-Watson CP, et al. Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study. Cephalalgia 1999; 19: 668-75
43. Sakai F. Safety and tolerability of rizatriptan. Cephalalgia 2000; 20 Suppl. 1: 16-8
44. Saper JR. The use of rizatriptan in the treatment of acute, multiple migraine attacks. Neurology 2000; 55 Suppl. 2: S15-8
45. Stark S, Spierings ELH, McNeal S, et al. Naratriptan efficacy in migraineurs who respond poorly to oral sumatritpan. Headache 2000; 40: 513-20
46. Tfelt-Hansen P, Goadsby PJ. Naratriptan is effective and well tolerated in the acute treatment of migraine. Neurology 1999 Apr; 52 (6): 1300-1
47. Sandrini G, Fäkkila M, Burgess G, et al. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology 2002; 59: 1210-7
48. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1-96
49. Nappi G, Savoldi F. Headache: diagnostic system and taxonomic criteria. London: John Libbey & Company Ltd, 1985
50. Silberstein SD, Lipton RB, Goadsby PJ. Headache in clinical practice. Oxford: Isis Medical Media Ltd, 1998
51. Rasmussen BK, Jensen R, Schroll M, et al. Epidemiology of headache in the general population: a prevalence study. J Clin Epidemiol 1991; 44: 1147-57
52. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the united States. JAMA 1992; 267: 64-9
53. Lipton RB, Stewart WF, von Korff M. Burden of migraine: societal costs and therapeutic opportunities: Neurology 1997; 48 Suppl 5: S4-S9
54. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol 1984; 16: 157-68
55. Hargreaves RJ, Shepheard SL. Pathophysiology of migraine: new insights. Can J Neurol Sci 1999; 26 Suppl. 3: S12-9
56. Ellrich J, Messlinger K, Chiang CY, et al. Modulation of neuronal activity in the nucleus raphè magnus by the 5-HT1-receptor agonists naratriptan in rat. Pain 2001; 90: 227-31
57. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive neuropeptide release in the extracerebral circulation during migraine headache. Ann Neurol 1990; 28: 183-7
58. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 48-56
59. Silberstein SD, Lipton RB, Dalessio DJ. Wolff's headache and other head pain. 7th ed. New York: Silberstein, Lipton & Dalessio, 2001
60. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996; 384: 560-4
61. Burstein R, Yamamura H, Malick A. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998; 79: 964-82
62. Bouchelet I, Cohen Z, Case B, et al. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 1998; 50: 219-23
63. Burstein R, Yamitsky D, Goor-Arych J, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47: 614-24
64. Block GA, Goldstein J, Polls A, et al. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Headache 1998; 38: 764-71
65. Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache 1991; 31: 365-71
66. Proietti-Cecchini A, Afra J, Schoenen J. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig). Cephalalgia 1997; 17 (8): 849-54
67. Connor HE, Feniuk W, Beattie DT, et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 1997; 17: 145-52
68. Goadsby PJ, Knight Y. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT1/B1D) receptors. Br J Pharmacol 1997; 122: 918-22
69. Moret C, Briley M. 5-HT autoreceptors in the regulation of 5-HT release from guinea-pig raphe nucleus and hypothalamus. Neurpharmacol 1997; 36 (11/12): 1713-23
70. Bou J, Domènech T, Puig J, et al. Pharmacological characterisation of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol 2000; 410: 33-41
71. Gras J, Bou J, Llenas J, et al. Functional profile of almotriptan in animal models predictive of antimigraine activity. Eur J Pharmacol 2000; 410: 43-51
72. Johnson DE, Rollema H, Schmidt AW, et al. Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Ear J Pharmacol 2001; 425: 203-10
73. Edmeads JG, Millson DS. Tolerability profile of zolmitriptan (Zomig TM; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. Cephalalgia 1997; 17 Suppl. 18: 41-52
74. Simmons VE, Blakebourough P. The safety profile of sumatriptan. Rev Contemp Pharmacother 1994; 5: 319-28
75. Gross MLP, Kay J, Turner AM, et al. Long-term efficacy of subcutaneous sumatriptan using a novel self-injector. Headache 1995; 35: 601-6
76. The International 311C90 Long-term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine: an international study. Headache 1998; 38: 173-83
77. Frid A, Hardebo JE. The thigh may not be suitable as an injection site for patients self injecting sumatriptan. Neurology 1997; 49: 559-61
78. Welch KMA, Mathew NT, Stone P, et al. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000; 20: 687-95
79. Tfelt-Hansen P, Block G. Dahlöf C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20: 765-86
80. Goadsby PJ. A triptan too far? J Neurol Neurosurg Psychiatry 1998; 64: 143-7
81. Salonen R. Drug comparisons: why are they so difficult? Cephalalgia 2000; 20 Suppl. 2: 25-32
82. Ekland A, McDaris HL, Satin L, et al. Cardiovascular safety of frovatriptan in patients at high risk of or with coronary artery disease during a migraine attack. Cephalagia 1999; 19: IIGI-35
83. O'Quinn S, Davis RL, Gutterman DL, et al. Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. Cephalalgia 1999; 19: 223-31
84. EEC notes for Guidances. Good clinical practice for trials on medicinal products in the European Community. Pharmacol Toxicol 1990; 67: 361-72
85. Dixon Jr JR. The international conference on harmonization good clinical practice guideline. Qual Assur 1998; 6: 65-74
86. Dahlöff CGH, Mathew N. Cardiovascular safety of 5-HT1B/1D agonists: is there a cause for concern? Cephalalgia 1998; 18: 539-45
87. Dahlöff CGH, Ekborn K, Persson L. Clinical experiences from Sweden on the use of subcutaneously administered sumatriptan in migraine and cluster headache. Arch Neurol 1994; 51: 1256-61
88. Visser WH, Jaspers NM, De Vriend RH, et al. Chest symptoms after sumatriptan: a two-year clinical practise review in 735 consecutive migraine patients. Cephalalgia 1996; 16: 554-9
89. Houghton LA, Foster JM, Whorwell PJ. et al. Is chest pain after sumatriptan oesophageal in origin? Lancet 1994; 314: 985-6
90. Nelson JA, Norris L. Welch KMA. Disturbance of muscle mitochondrial function is associated with side effects of sumatriptan. Cephalalgia 1997; 17: 427
91. Maassen VanDenBrink A, Bax WA, Ferrari MD, et al. Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane. Br J Pharmacol 1996; 119: 855-62
92. Visser WH, de Vriend RH, Jaspers MW, et al. Sumatriptan in clinical practice: a 2 year review of 453 migraine patients. Neurology 1996; 47: 46-51
93. Loi V, Cherchi A, Pisano R, et al. Can sumatriptan be anxiogenic in migraineurs? Cephalalgia 1996; 16: 36-7
94. Cipolla G, Sacco S, Crema F, et al. Gastric motor effects of triptans: open questions and future perspectives. Pharmacol Res 2001; 43 (3): 205-10
95. Hood S, Birnie D, MacIntyre PD, et al. Sumatriptan-induced chest pain [letter comment]. Lancet 1994; 334:1500-1
96. Carel I, Ghaleh B, Edouard A, et al. Comparative effects of frovatriptan and sumatritpan on coronary and internal carotid vascular haemodynamics in conscious dogs. Br J Pharmacol 2001; 132: 1071-83
97. De Vries P, Willems EW, Heiligers JPC, et al. Investigation of the role of 5-HT1B and 5-HT1D receptors in the sumatritpan-induced constriction of porcine carotid arteriovenous anastomoses. Br J Pharmacol 1999; 127: 405-12
98. Gnecchi-Ruscone T, Bernard X, Pierre P, et al. Effect of naratriptan on myocardial blood flow and coronary vasodilator reserve in migraineurs. Neurology 2000; 55: 95-9
99. Muir DF, McCann GP, Swan L, et al. Hemodynamic and coronary effects of intravenous eletriptan, a 5-HT1B/1D-receptor agonist. Clin Pharmacol Ther 1999; 66: 85-90
100. Parsons AA, Valocik R, Koster P, et al. Effects of the novel antimigraine agent, frovotriptan, on coronary and cardiac function in dogs. J Cardiovasc Pharmacol 1998; 32: 995-1000
101. VanDenBrink AM, van den Broek RWM, De Vries R, et al. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 2000; 55: 1524-30
102. Bax WA, Renzenbrink GJ, Van Heuven-Nolsen D, et al. 5-HT receptors mediating contractions of the isolated human coronary artery. Eur J Pharmacol 1993; 239: 203-10
103. Connor HE, Feniuk W, Humphrey PP. 5-Hydroxytryptamine, contracts human coronary arteries predominantly via 5-HT2 receptor activation. Eur J Pharmacol 1989; 161: 91-4
104. Maassen Van Den Brink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective anti-migraine drugs. Circulation 1998; 98: 25-30
105. Maassen Van Den Brink A, Van Den Broek RWM, De Vries R, et al. Human middle meningeal and coronary artery contraction to eletriptan and sumatriptan. Cephalalgia 1999; 19: 398
106. Gras J, Cardelùs I, Llenas J, et al. Cardiovascular safety profile of almotriptan, a new indolic derivative for the treatment of migraine. Eur J Pharmacol 2000; 410: 53-9
107. Napier C, Stewart M, Melrose H, et al. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol 1999; 368: 259-68
108. Van den Broek RWM, VanDenBrink AM, De Vries R, et al. Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels. Eur J Pharmacol 2000; 407: 165-73
109. Goldstein DJ, Roon KI, Offen WW, et al. Selective seratonin 1F(5-HT1F) receptor agonists LY334370 for acute migraine: a randomised controlled trial. Lancet 2001; 358: 1230-4
110. Bax WA, Renzenbrink GJ, Van Heuven-Nolsen D, et al. 5-HT receptors mediating contractions of the isolated human coronary artery. Eur J Pharmacol 1993; 239: 203-10
111. Saxena PR, De Vries P, Wang W, et al. Effects of avitriptan, a new 5-HT1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: 295-302
112. Cavazos JE, Carees JB, Chilukuri VR. Sumatriptan-induced stroke in sagittal sinus thrombosis. Lancet 1994; 343: 1105-8
113. Knudsen JF, Friedman B, Chen M, et al. Ischemic colitis and sumatriptan use. Arch Intern Med 1998; 158: 1946-8
114. Mueller L, Gallagher RM, Ciervo CA. Vasospasm-induced myocardial infarction with sumatriptan. Headache 1996; 36: 329-31
115. O'Connor P, Gladstone P. Oral sumatriptan-associated transmural myocardial infarction. Neurology 1995; 45: 2274-6
116. Ottervanger JP, Wilson HJP, Stricker BHC. Drug-induced chest pain and myocardial infarction: reports to a national centre and review of the literature. Eur J Clin Pharmacol 1997; 53 (2): 105-10
117. Sternfeld B. Stang P, Sidney S. Relationship of migraine headaches to experience of chest pain and subsequent risk for myocardial infarction. Neurology 1995; 45: 2135-42
118. Dahlöff CGH, Falk L, Rosenfors M, et al. Safety trial with the 5-HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan. Cephalalgia 1998; 18: 546-51
119. Miles CB. Treatment of migraine during pregnancy and lactation. S D J Med. 1995; 48: 373-7
120. Maggioni F, Alessi C, Maggino T, et al. Headache during pregnancy. Cephalalgia 1997; 17: 765-79
121. Silberstein SD. Headache and female hormones: what you need to know. Curr Opin Neurol 2001; 14: 323-33
122. Olesen C, Steffensen FH, Sørensen HT. et al. Pregnancy outcome following prescription for sumatriptan. Headache 2000; 40: 20-4
123. Käillén B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 2001; 41: 351-6
124. Reiff-Eldridge R, Heffner CR, Ephross SA, et al. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol 2000; 182: 159-63
125. Shuhaiber S, Pastuszak A, Schick B, et al. Pregnancy outcome following first trimester exposure to sumatriptan. Neurology 1998; 51: 581-3
126. Hoskins SP. Ergotarnine use in pregnancy. Aust N Z J Obstet Gynecol 1996; 36: 159-60
127. Newman L, Mannix LK, Landy S, et al. Naratritpan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache 2001; 41: 248-56
128. Katsarava Z, Fritsche G, Muessig M, et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57: 1694-8
129. Limmroth V, Kazarawa Z, Fritsche G, et al. Headache after frequent use of serotonin agonists zolmitriptan and naratriptan. Lancet 1999 Jan 30; 353: 378
130. Göbel H, Lindner V, Heinze A, et al. Acute therapy for cluster headache with sumatriptan: findings of a one-year long-term study. Neurology 1998; 51: 908-11
131. Monstad I, Krabbe A, Micieli G, et al. Preemptive oral treatment with sumatriptan during a cluster period. Headache 1995; 35: 607-13
132. Dowson A. Drug-induced headaches. Lancet 1999; 354: 254-5
133. Ferrari MD, James MH, Bates D, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 1994; 14: 330-8
134. Sheftell FD, O'Quinn S, Watson C, et al. Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. Headache 2000; 40: 103-10
135. Visser WH, Jaspers NMWH, de Vriend RHM, et al. Risk factors for headache recurrence after sumatriptan: a study in 336 migraine patients. Cephalalgia 1996; 16: 264-9
136. Fox AW. Comparative tolerability of oral 5-HT1B/1D agonists. Headache 2000; 40: 521-7
137. Dixon R, Warrander A. The clinical pharmacokinetics of zolmitriptan. Cephalalgia 1997; 17 Suppl. 18: 15-20
138. Millson D. Clinical pharmacokinetics of the triptans: what are the important clinical issues? In: Humphrey P, Ferrari M, Olesen J, editors. The triptans, novel drugs for migraine: frontiers in headache research. Oxford; Oxford University Press, 2001
139. Choo EF, Laeke B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-I protease inhibitors into brain and testes. Drug Met Disp 2000; 28: 655-60
140. Kim RB, Wandel C, Leake B. et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprorein. Pharm Res 1999; 16: 408-14
141. Millson D, Frischer M, Croft P, et al. Are triptans with enhanced lipophilicity used for the acute treatment of migraine associated with an increased consulting rate for depressive illness? Cephalalgia 2000; 20: 732-7
142. Fleishaker JC, Ryan KK, Jansat JM, et al. Effect of MAO-A inhibition on the pharmacokenetics of almotriptan, an anti-migraine agent in humans. J Clin Pharmacol 2001; 51: 437-41
143. Newman-Tancredi A, Come C, Chaput C, et al. Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. Naunyn Schmiedeberg's Arch Pharmacol 1997; 335: 682-8
144. Fleishaker JC, Sisson TA, Carel BJ, et al. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther 2000; 67: 498-503
145. TM), 311C90). Cephalalgia 1997; 17 Suppl. 18: 21-7
146. Willems EW, Trion M, De Vries P, et al. Pharmacological evidence that α- and α-adrenoceptors mediate vasoconstriction of carotid arteriovenous anastomoses in anaesthetized pigs. Br J Pharmacol 1999; 127: 1263-71